Back to today’s briefing

Story perspectives

Eli Lilly’s Kisunla Approved: 35% Cognitive Decline Slowdown!

5/23/2025

33 3

Summary

Story summary

Eli Lilly's groundbreaking drug, Kisunla (donanemab), has been approved in Australia to treat early symptomatic Alzheimer's disease in adults with certain genetic markers. This pioneering therapy can slow cognitive decline by an impressive 35%, and once amyloid plaques are cleared, treatment may even be halted. However, genetic testing is essential to monitor potential side effects.

1 of 1

Story summary

Eli Lilly's groundbreaking drug, Kisunla (donanemab), has been approved in Australia to treat early symptomatic Alzheimer's disease in adults with certain genetic markers. This pioneering therapy can slow cognitive decline by an impressive 35%, and once amyloid plaques are cleared, treatment may even be halted. However, genetic testing is essential to monitor potential side effects.